Prediction of adverse pregnancy outcome by the presence of lupus anticoagulant, but not anticardiolipin antibody, in patients with antiphospholipid antibodies.

No abstract is available for this paper.

• Publication year

  2012

• Venue

  Arthritis & Rheumatism

• Publication date

  2012-07-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1002/art.34402PMID 22275304PMCID PMC3357451
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• In vivo distribution of β2 glycoprotein I under various pathophysiologic conditions.

  2011cited by this paper
• Risk factors for pregnancy failure in patients with anti-phospholipid syndrome treated with conventional therapies: a multicentre, case-control study.

  2011cited by this paper
• Moderate versus high-titer persistently anticardiolipin antibody positive patients: Are they clinically different and does high-titer anti-β2-glycoprotein-I antibody positivity offer additional predictive information?

  2010cited by this paper
• Association of Anticardiolipin Antibodies With Preeclampsia: A Systematic Review and Meta-Analysis

  2010cited by this paper
• Laboratory and clinical features of pregnant women with antiphospholipid syndrome and neonatal outcome

  2010cited by this paper
• Lupus anticoagulant testing: performance and practices by north american clinical laboratories.

  2010cited by this paper
• Anti-beta(2)-glycoprotein-I and anti-phosphatidylserine antibodies in women with spontaneous pregnancy loss.

  2010cited by this paper
• Update of the guidelines for lupus anticoagulant detection

  2009cited by this paper
• Lupus and the Antiphospholipid Syndrome in Pregnancy and Obstetrics: Clinical Characteristics, Diagnosis, Pathogenesis, and Treatment

  2008cited by this paper
• Are laboratories following published recommendations for lupus anticoagulant testing?

  2008cited by this paper
• Laboratory testing for lupus anticoagulants: a review of issues affecting results.

  2007cited by this paper
• Relationship between Thrombophilic Disorders and Type of Severe Early-Onset Hypertensive Disorder of Pregnancy

  2007cited by this paper
• Antibody profile and clinical course in primary antiphospholipid syndrome with pregnancy morbidity

  2006cited by this paper
• International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS)

  2006cited by this paper
• The obstetric antiphospholipid syndrome.

  2006cited by this paper
• Real world experience with antiphospholipid antibody tests: how stable are results over time?

  2005cited by this paper
• Antiphospholipid antibodies as cause of pregnancy loss

  2004cited by this paper
• Treatment of antiphospholipid syndrome in pregnancy--a systematic review of randomized therapeutic trials.

  2004cited by this paper
• Antiphospholipid antibodies and fetal compromise.

  2004cited by this paper
• ACOG Practice Bulletin No. 58. Ultrasonography in pregnancy.

  2004cited by this paper
• A modified poisson regression approach to prospective studies with binary data.

  2004cited by this paper
• The prevalence of lupus anticoagulant in normal pregnancy and in women with recurrent fetal loss—recommendations for laboratory testing for lupus anticoagulant

  2004cited by this paper
• ACOG practice bulletin. Diagnosis and management of preeclampsia and eclampsia. Number 33, January 2002.

  2002cited by this paper
• Dual antibody reactivity to β2-glycoprotein I and protein S: increased association with thrombotic events in the antiphospholipid syndrome

  2002cited by this paper
• Use of the dilute Russell viper venom time (dRVVT): its importance and pitfalls.

  2000cited by this paper
• International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop.

  1999cited by this paper
• Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus.

  1997cited by this paper
• Vitamin C intake and susceptibility to pneumonia.

  1997cited by this paper
• Randomised controlled trial of aspirin and aspirin plus heparin in pregnant women with recurrent miscarriage associated with phospholipid antibodies (or antiphospholipid antibodies)

  1997cited by this paper
• A United States National Reference for Fetal Growth

  1996cited by this paper
• Antiphospholipid Antibodies and Fetal Death

  1996cited by this paper
• Frequency of factors associated with habitual abortion in 197 couples.

  1996cited by this paper
• Antiphospholipid antibody-associated recurrent pregnancy loss: treatment with heparin and low-dose aspirin is superior to low-dose aspirin alone.

  1996cited by this paper
• Characteristics of high-titer IgG antiphospholipid antibody in systemic lupus erythematosus patients with and without fetal death.

  1990cited by this paper
• Special report. The Second International Anti-cardiolipin Standardization Workshop/the Kingston Anti-Phospholipid Antibody Study (KAPS) group.

  1990cited by this paper

• Obstetric antiphospholipid syndrome: Advances in pathogenesis.

  2026cites this paper
• A Re-evaluation of Obstetric Antiphospholipid Syndrome

  2025cites this paper
• Deciphering the Role and Mechanism of Decidual Monocyte‐Derived Macrophage Infiltration in Obstetric Antiphospholipid Syndrome at Single‐Cell Resolution

  2025cites this paper
• Thrombin generation test as a useful tool for improving disease severity stratification in antiphospholipid syndrome

  2025cites this paper
• New ACR/EULAR 2023 classification criteria for antiphospholipid syndrome, what should a gynaecologist know in 2025.

  2025cites this paper
• Prevalence of antiphospholipid syndrome among women with recurrent pregnancy loss: a cohort study

  2025cites this paper
• Prognostic Value of Lupus Anticoagulant and Anti–β2 Glycoprotein I Antibody in Adverse Pregnancy Outcomes

  2025cites this paper
• Fetal and maternal outcome in the pregnancies of patients with systemic sclerosis and very early diagnosis of systemic sclerosis in France: a prospective study.

  2025cites this paper
• Predictors of adverse pregnancy outcomes in systemic lupus erythematosus: A retrospective cohort study

  2025cites this paper
• Novel advances on pathophysiological mechanisms, clinical manifestations, and treatment of antiphospholipid syndrome

  2025cites this paper
• Progress in APS pregnancy: Results from the IMPACT trial.

  2025cites this paper
• Coagulation Parameters in Singleton and Twin Pregnancies

  2025cites this paper
• Association Study of Hyaluronan-Binding Protein 2 (HABP2) Gene Polymorphisms in Idiopathic Recurrent Pregnancy Loss (RPL) in Korean Women

  2025cites this paper
• Complement proteins, annexin V, and angiogenic markers in placental tissue of autoimmune disease patients.

  2025cites this paper
• Certolizumab pegol to prevent adverse pregnancy outcomes in patients with antiphospholipid syndrome and lupus anticoagulant (IMPACT): results of a prospective, single-arm, open-label, phase 2 trial.

  2025cites this paper
• Establishment Trimester-Specific Reference Intervals of Anticoagulation and Fibrinolysis Indicators in Healthy Pregnant Women in Beijing, China

  2025cites this paper
• Systemic lupus erythematosus and risk factors for adverse outcomes in pregnancy: a single center retrospective cohort study in Northern Brazil

  2025cites this paper
• Recurrent Pregnancy Loss

  2025cites this paper
• Towards precision medicine in antiphospholipid syndrome.

  2025cites this paper
• Risk factors for adverse pregnancy outcomes in systemic lupus erythematosus: a meta-analysis and systemic review

  2025cites this paper
• Clinical, immunological features and relation to clinical phenotypes in patients with antiphospholipid syndrome

  2025cites this paper
• Antiphospholipid-exposed trophoblast-derived extracellular vesicles express elevated levels of TLR7/8-activating microRNAs and induce endometrial endothelial activation, in part, through TLR7.

  2024cites this paper
• Sub-segmental pulmonary thromboembolism in a pregnant woman with generalized lupus erythematosus, triple-negative antiphospholipid syndrome, and protein C deficiency. A case report

  2024cites this paper
• Risk Factors for Adverse Pregnancy Outcomes in Patients with Antiphospholipid Syndrome

  2024cites this paper
• Impact of Antiphospholipid Syndrome on Reproductive Outcomes: Current Insights and Management Approaches

  2024cites this paper
• Challenging cases in rheumatic disease pregnancy: management perspectives from reproductive rheumatologists

  2024cites this paper
• Single-cell transcriptome analyses reveal disturbed decidual homoeostasis in obstetric antiphospholipid syndrome

  2024cites this paper
• Risk factors for damage accrual in primary antiphospholipid syndrome: A retrospective single-center cohort study.

  2024cites this paper
• Acute peripartum pancreatitis complicating seronegative antiphospholipid antibody syndrome in pregnancy

  2024cites this paper
• Efficacy and safety of low-dose acetylsalicylic acid for the prevention of thromboembolic events in individuals positive for antiphospholipid antibodies: A systematic review and meta-analysis.

  2024cites this paper
• Thrombotic Microangiopathy in Pregnancy: Current Understanding and Management Strategies

  2024cites this paper
• ОСОБЕННОСТИ ВЕДЕНИЯ БЕРЕМЕННЫХ С СИСТЕМНОЙ КРАСНОЙ ВОЛЧАНКОЙ И АНТИФОСФОЛИПИДНЫМ СИНДРОМОМ

  2024cites this paper
• Challenges of designing and conducting cohort studies and clinical trials in populations of pregnant people.

  2024cites this paper
• Facteurs associés à la morbi-mortalité néonatale chez 267 patientes porteuses d’un syndrome des antiphospholipides incluses dans l’étude prospective du GR2

  2024cites this paper
• Construction and application of fetal loss risk model in systemic lupus erythematosus patients with mild disease severity

  2024cites this paper
• Biological markers of high risk of thrombotic recurrence in patients with antiphospholipid syndrome: A literature review.

  2024cites this paper
• Association Between Novel Antiphospholipid Antibodies and Adverse Pregnancy Outcomes

  2024cites this paper
• Pregnancy outcome predictors in systemic lupus erythematosus: prospective for brighter perspectives.

  2024cites this paper
• Criteria and non-criteria antiphospholipid autoantibodies screening in patients with late pregnancy morbidity: A cross-sectional study.

  2024cites this paper
• Dilemmas in the Diagnosis and Management of Antiphospholipid Syndrome.

  2024cites this paper
• 产科抗磷脂综合征的诊治原则与热点问题述评

  2024cites this paper
• Therapeutic changes of systemic lupus erythematosus (SLE) patients in pregnancy and feto-maternal outcomes: a retrospective cohort study

  2024cites this paper
• Comparison of different algorithms for lupus anticoagulant detection: a single-center experience

  2024cites this paper
• Obstetric antiphospholipid syndrome carries an increased lifetime risk for obstetric and thrombotic complications—a population-based study

  2024cites this paper
• Added IMPACT: The first successful natural birth using certolizumab in obstetric APS.

  2024cites this paper
• Reproductive Health in RA, Lupus, and APS

  2024influential citation
• The prevalence of antiphospholipid antibodies and effects on the outcomes of in vitro fertilization

  2024cites this paper
• Cluster analysis of antiphospholipid antibodies-associated adverse pregnancy outcome patients: based on a 13-years cohort study

  2023influential citation
• Management of Rheumatic Diseases During Pregnancy and Breastfeeding

  2023influential citation
• Antiphospholipid Syndrome: State of the Art of Clinical Management

  2023cites this paper
• Hemorrhage complications in obstetric antiphospholipid syndrome: Risk factors and association with adverse pregnancy outcomes

  2023cites this paper
• Machine learning application in autoimmune diseases: State of art and future prospectives.

  2023cites this paper
• HOW I DIAGNOSE AND TREAT ANTIPHOSPHOLIPID SYNDROME IN PREGNANCY.

  2023cites this paper
• Exosomal miR-146a-5p derived from human umbilical cord mesenchymal stem cells can alleviate antiphospholipid antibody-induced trophoblast injury and placental dysfunction by regulating the TRAF6/NF-κB axis

  2023cites this paper
• Assessing disease activity and damage in antiphospholipid syndrome.

  2023cites this paper
• Effect of residual platelets in frozen-thawed plasma on results of dilute Russell's viper venom time assay for lupus anticoagulant testing.

  2023cites this paper
• Positive antiphospholipid antibodies: observation or treatment?

  2023cites this paper
• Anti-β2-glycoprotein I and anti-phosphatidylserine/prothrombin antibodies interfere with cleavage of factor V(a) by activated protein C.

  2023cites this paper
• Pregnancy outcomes in women with primary Sjögren's syndrome: an analysis of data from the multicentre, prospective, GR2 study.

  2023cites this paper
• Management and outcomes of women with antiphospholipid syndrome during pregnancy

  2023cites this paper
• Pregnancy outcomes in 1869 pregnancies in a large cohort from the Spanish Society of Rheumatology Lupus Register (RELESSER).

  2023cites this paper
• Triphasic: Preeclampsia, Systemic Lupus Erythematosus, and Severe Neutropenia With Use of Granulocyte Colony Stimulating Factor in the Partum and Postpartum Period

  2023cites this paper
• Antiphospholipid syndrome: advances in diagnosis, pathogenesis, and management

  2023cites this paper
• Challenges in Family Planning and Pregnancy for Women with Rheumatic Diseases

  2023cites this paper
• Antiphospholipid syndrome management: a 2023 update and practical algorithm-based approach

  2023cites this paper
• Alternative pathway activation in pregnancy, a measured amount “complements” a successful pregnancy, too much results in adverse events

  2022cites this paper
• Early Prediction of Adverse Pregnancy Outcome in Women with Systemic Lupus Erythematosus, Antiphospholipid Syndrome, or Non-Criteria Obstetric Antiphospholipid Syndrome

  2022cites this paper
• Pregnancy outcomes in antiphospholipid antibody positive patients: prospective results from the AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION) Clinical Database and Repository (‘Registry’)

  2022cites this paper
• British Society for Rheumatology guideline on prescribing drugs in pregnancy and breastfeeding: immunomodulatory anti-rheumatic drugs and corticosteroids

  2022cites this paper
• Obstetric management of the most common autoimmune diseases: A narrative review

  2022cites this paper
• Society for Maternal-Fetal Medicine (SMFM) Consult Series #64 : Systemic lupus erythematosus in pregnancy.

  2022cites this paper
• Characterisation of a high-risk profile for maternal thrombotic and severe haemorrhagic complications in pregnant women with antiphospholipid syndrome in France (GR2): a multicentre, prospective, observational study.

  2022cites this paper
• Adverse pregnancy outcomes in women with systemic lupus erythematosus: can we improve predictions with machine learning?

  2022cites this paper
• Enfoque del síndrome antifosfolipidos en el embarazo

  2022cites this paper
• Laboratory Diagnosis of Antiphospholipid Syndrome: Insights and Hindrances

  2022cites this paper
• Obstetric Antiphospholipid Syndrome From the Perspective of a Rheumatologist

  2022cites this paper
• Treatment of Refractory/High-Risk Pregnancies With Antiphospholipid Syndrome: A Systematic Review of the Literature

  2022cites this paper
• Reference intervals for coagulation parameters in non-pregnant and pregnant women

  2022cites this paper
• Association between interferon-I producing plasmacytoid dendritic cells and thrombotic antiphospholipid syndrome

  2022cites this paper
• Antiphospholipid Antibodies Increase the Risk of Fetal Growth Restriction: A Systematic Meta-Analysis

  2022influential citation
• Clinical and Immunologic Profile of Women with Recurrent Pregnancy Losses in the Philippine General Hospital

  2022cites this paper
• Anti-phosphatidylserine/prothrombin complex antibodies (aPS/PT) increase the risk for thrombosis based on lupus anticoagulant positivity.

  2022cites this paper
• Anticardiolipin IgA as a Potential Risk Factor for Pregnancy Morbidity in Patients with Antiphospholipid Syndrome.

  2022cites this paper
• Pathogenesis, Diagnosis and Management of Obstetric Antiphospholipid Syndrome: A Comprehensive Review

  2022cites this paper
• The impact of hydroxychloroquine on obstetric outcomes in refractory obstetric antiphospholipid syndrome.

  2021cites this paper
• Obstetric anti-phospholipid syndrome: from pathogenesis to treatment

  2021cites this paper
• Maternal Systemic Lupus Erythematosus (SLE) High Risk for Preterm Delivery and Not for Long-Term Neurological Morbidity of the Offspring

  2021cites this paper
• Risk Factors for the Development of the Disease in Antiphospholipid Antibodies Carriers: A Long-term Follow-up Study

  2021cites this paper
• Systemic lupus erythematosus and pregnancy: Strategies before, during and after pregnancy to improve outcomes

  2021cites this paper
• Comparison of Different Test Systems for the Detection of Antiphospholipid Antibodies in a Chinese Cohort

  2021cites this paper
• Reply

  2021cites this paper
• Single or triple positivity for antiphospholipid antibodies in “carriers” or symptomatic patients: Untangling the knot

  2021cites this paper
• A Novel Autoantibody against β2-Glycoprotein I/HLA Class II Complexes in Antiphospholipid Syndrome

  2021cites this paper
• Is the presence of antiphospholipid antibodies a poor prognostic factor for patients with HELLP syndrome?

  2021cites this paper
• Anti-phospholipid antibodies in women presenting with preterm delivery because of preeclampsia or placental insufficiency

  2021cites this paper
• Antithrombotic therapy to prevent recurrent pregnancy loss in antiphospholipid syndrome—What is the evidence?

  2021cites this paper
• Fertility and pregnancy outcomes in patients with immune-mediated rheumatic diseases

  2021cites this paper
• Anti‐β2‐glycoprotein I and anti‐prothrombin antibodies cause lupus anticoagulant through different mechanisms of action

  2021cites this paper
• Association between HOX Transcript Antisense RNA Single-Nucleotide Variants and Recurrent Implantation Failure

  2021cites this paper
• Management of patients with antiphospholipid antibodies: what to do in laboratory scenarios that do not fit the guidelines

  2021cites this paper